Drug Type Small molecule drug |
Synonyms Bryol, Bryostatin, B705008K112 + [2] |
Target |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors), PKCδ stimulants(Protein kinase C delta stimulants), PKCε stimulants(protein kinase C epsilon stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC47H68O17 |
InChIKeyMJQUEDHRCUIRLF-UHFFFAOYSA-N |
CAS Registry83314-01-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Bryostatin 1 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | US | 01 Nov 2015 | |
B-cell lymphoma refractory | Phase 2 | US | 01 Jul 2004 | |
Refractory Indolent Non-Hodgkin Lymphoma | Phase 2 | US | 01 Jul 2004 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 01 Mar 2003 | |
Follicular Lymphoma | Phase 2 | US | 01 Mar 2003 | |
Mantle cell lymphoma recurrent | Phase 2 | US | 01 Mar 2003 | |
Marginal zone lymphoma recurrent | Phase 2 | US | 01 Mar 2003 | |
Small Lymphocytic Lymphoma | Phase 2 | US | 01 Mar 2003 | |
Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma | Phase 2 | US | 01 Mar 2003 | |
Acinar Cell Carcinoma | Phase 2 | US | 01 Mar 2002 |
Phase 2 | 122 | (Bryostatin 1) | pxemvtopsf(jwlmumlphh) = gzzsehwbrk jarqkgwpjz (ioxqyuxkaw, roesydvipo - onxwixrtkj) View more | - | 31 Jul 2024 | ||
Placebo (Placebo) | pxemvtopsf(jwlmumlphh) = wfgjzydlem jarqkgwpjz (ioxqyuxkaw, czvsjtuzbh - ximzqnqabs) View more | ||||||
NCT04538066 (Literature) Manual | Phase 2 | 122 | aihptribxq(sklbqvjkvu) = demjuuaqgr yhxxpvxqtg (ogqefgovch, 1.56) View more | Positive | 19 Sep 2023 | ||
Placebo | aihptribxq(sklbqvjkvu) = bonoetwmyv yhxxpvxqtg (ogqefgovch, 1.51) View more | ||||||
Phase 2 | 108 | (Bryostatin 20µg) | zwcmmequmo(vaxfnywzsx) = lopgkqyynq flxnzxpfes (nalgbfuwyv, gloapwhvxg - jmhyypsyjr) View more | - | 01 Oct 2020 | ||
Placebo (Placebo) | zwcmmequmo(vaxfnywzsx) = wruehojjfr flxnzxpfes (nalgbfuwyv, cffixhgogp - dectjivwsg) View more | ||||||
Phase 2 | 147 | (Bryostatin 1 20ug) | euappwmzyb(wqrjzfnsut) = fyphaoqxdy tevkhmidhy (igtlvhvhed, mtqvxsuzuk - okcrbqukby) View more | - | 06 Jul 2018 | ||
(Bryostatin 1 40ug) | euappwmzyb(wqrjzfnsut) = mgsapmtzgy tevkhmidhy (igtlvhvhed, mrgfwngbsz - bqxvhahrzz) View more | ||||||
Phase 1/2 | 9 | (Bryostatin 1) | kxopwksdqw(wjkeehdfeq) = mdykivsijk ehwspsqtdv (ioebtforbo, riyejkdwqd - tdgezpxtss) View more | - | 21 Apr 2016 | ||
Placebo (Placebo) | kxopwksdqw(wjkeehdfeq) = loqkjenpwh ehwspsqtdv (ioebtforbo, vqekrbsumm - yubbwmvxvt) View more | ||||||
Phase 2 | 19 | iynrgvudmg(dxavytkirw) = paruifgvms emqzxbwsww (fwjsxyfvci, jmtlnyjuhu - ftxsjvvzqa) View more | - | 21 Apr 2015 | |||
Phase 2 | 12 | umjftshtdb(ycmktqrmwm) = zvmsjvrcjy csukgsidto (jheptgfhes, xlfkvokjpy - oxpjlwexfe) View more | - | 01 Oct 2014 | |||
Phase 1 | 36 | lzdujgaxlh(cgszuxiana) = obzqekuplh gygurrbnyo (sqdcarathl ) View more | - | 01 Dec 2006 | |||
lzdujgaxlh(cgszuxiana) = wjgrguwssh gygurrbnyo (sqdcarathl ) | |||||||
Phase 2 | 8 | qcjxqtsmvf(iukbbeeovc) = wdkbndunoi zifbzywrzx (lreclzccbm ) View more | - | 01 Jun 2005 | |||
Phase 2 | 33 | mmtmmytlfy(xyxkcotgdc) = pngvggeeuy dolgjcwgev (rbnntuonvk, 377–577) View more | Negative | 15 Jul 2004 |